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Abstract
Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of phosphatidylinositol-3
kinase (PI3K), have been shown to transform mammary epithelial cells (MECs). Studies suggest
this transforming activity requires binding of mutant p110α via p85 to phosphorylated YXXM
motifs in activated receptor tyrosine kinases (RTKs) or adaptors. Using transgenic mice, we
examined if ErbB3, a potent activator of PI3K, is required for mutant PIK3CA-mediated
transformation of MECs. Conditional loss of ErbB3 in mammary epithelium resulted in a delay of
PIK3CAH1047R-dependent mammary gland hyperplasia, but tumor latency, gene expression and
PI3K signaling were unaffected. In ErbB3-deficient tumors, mutant PI3K remained associated
with several tyrosyl phosphoproteins, potentially explaining the dispensability of ErbB3 for
tumorigenicity and PI3K activity. Similarly, inhibition of ErbB RTKs with lapatinib did not affect
PI3K signaling in PIK3CAH1047R-expressing tumors. However, the p110α-specific inhibitor
BYL719, in combination with lapatinib impaired mammary tumor growth and PI3K signaling
more potently than BYL719 alone. Further, co-inhibition of p110α and ErbB3 potently suppressed
proliferation and PI3K signaling in human breast cancer cells harboring PIK3CAH1047R. These
data suggest that PIK3CAH1047R-driven tumor growth and PI3K signaling can occur
independently of ErbB RTKs. However, simultaneous blockade of p110α and ErbB RTKs results
in superior inhibition of PI3K and mammary tumor growth, suggesting a rational therapeutic
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INTRODUCTION
Phosphatidylinositol-3-kinase (PI3K) is the most frequently mutated signaling pathway in
cancer, affecting tumor cell survival, proliferation, migration and metabolism (1, 2). PI3K is
a lipid kinase composed of a p85 regulatory subunit dimerized with a p110 catalytic subunit
(1, 3). The N-terminal SH2 domain of p85 binds to phosphorylated tyrosines in receptors or
adaptors; this binding relieves the p85-mediated inhibition of p110 which, as a result,
becomes activated and catalyzes the conversion of phosphatidylinositol-4,5-bisphosphate
(PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), a second messenger that recruits
signal transducers (Akt, PDK1, SGK, etc.) to the plasma membrane, where they become
activated (1).
The PI3K pathway is aberrantly activated by gain-of-function mutations in p110α
(PIK3CA) and p85α (PIK3R1), amplification of wild type PIK3CA, p110β (PIK3CB) and
PDK1, loss/inactivation of the PIP3 phosphatases PTEN and INPP4B, mutation and/or
amplification of AKT1-3, and amplification of RTKs (4, 5). Three “hotspot” mutations have
been identified in PIK3CA: E542K, E545K, and H1047R, accounting for ~80% of PIK3CA
mutations (2, 6, 7). PIK3CA mutations occur in approximately 40% of breast cancers,
mainly in tumors with luminal and HER2-enriched gene expression (8), where they have
been associated with a more virulent phenotype and resistance to anti-estrogen and anti-
HER2 therapy.
HER2/ErbB2 gene amplification occurs in 25% of breast cancers where it associates with
poor patient outcome. The main dimerization partner of HER2 is HER3/ErbB3. Six p85
binding motifs in ErbB3 activate PI3K (9, 10). ErbB3 is essential for PI3K activation and
survival of HER2-overexpressing breast cancer cells (9, 11, 12). Therapies that inhibit PI3K
induce ErbB3 expression and reactivation via feedback mechanisms which partially
maintain PI3K and counteract drug action. As such, the efficacy of HER2 and PI3K
inhibitors is improved by co-inhibition of ErbB3 (11, 13, 14).
In addition to ErbB2/ErbB3, other RTKs activate PI3K via insulin receptor substrate (IRS)
and Gab family molecules. These adaptors lack enzymatic activity, but when tyrosine
phosphorylated by RTKs, they recruit p85 (PI3K) and other signaling molecules (15, 16).
Activated RTKs, including insulin and IGF receptors, VEGFR, EGFR and ALK recruit IRS
adaptors (16, 17). IRS-1 has nine p85 binding motifs (18) and, like ErbB3, strongly activates
PI3K. Similarly, Gab1 and Gab2 contain three p85 binding motifs and are tyrosine
phosphorylated by ErbB2, MET, Abl, FGFR, EGFR and Src kinases (15). The p85 subunit
was discovered by its association with PDGFR, a potent activator of PI3K (19). Biochemical
analyses have shown that both PIK3CAE545K and PIK3CAH1047R exhibit ~two-fold higher
catalytic activity than wild type PI3K. The association of PIK3CAH1047R with PDGFR or
IRS-1 phosphopeptides further increases the catalytic activity of the mutant enzyme (20).
Additionally, PIK3CAH1047R association with p85 is required for transformation induced by
mutant PI3K (6, 21). These data suggest a role for upstream RTKs in the signaling output of
mutant PI3K, leading us to hypothesize that mutant PIK3CA requires upstream adaptors,
such as ErbB3, to induce epithelial transformation and tumor progression.
We show herein that mammary gland hyperplasia induced by temporally-regulated
expression of mutant PIK3CA was delayed in mice lacking ErbB3 in the mammary
epithelium. In contrast, tumor formation and PI3K activity were unaffected by ErbB3
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ablation. In tumors expressing ErbB3, mutant PI3K associated with several tyrosine-
phosphorylated proteins, including ErbB3. In tumors lacking ErbB3, PI3K still associated
with other upstream adaptors and RTKs. Inhibition of RTKs or adaptors known to activate
PI3K did not block cell growth or PI3K activity in mammary tumors or PIK3CA-mutant
human breast cancer cells. However, simultaneous inhibition of upstream RTKs and mutant
p110α more potently inhibited tumor growth and PI3K signaling than inhibition of p110α
alone. These data suggest that mutant PIK3CA still relies upon upstream activators and
combined inhibition of PI3K and these activators is a rational treatment strategy against
tumors harboring PIK3CA activating mutations.
MATERIALS AND METHODS
Cell Culture
MDA-MB-453 and T47D cells were from ATCC. MDA-MB-453 were authenticated in
March 2013 by short tandem repeat (STR) DNA analysis (DDC Medical); authentication of
T47D cells (March 2011) has been described (22). CAL-148 and BT20 cells were provided
and authenticated as described (23). All cells were cultured in DMEM with 10% FBS (Life
Technologies). EZN-3920 and EZN-4455 are locked nucleic acid antisense molecules
provided by Enzon Pharmaceuticals (11, 24); they were resuspended in sterile PBS to a
stock concentration of 5 mM and applied to cells at 5 μM in the absence of transfection
reagent. EZN-3920 targets ErbB3 and EZN-4455 is a scrambled control antisense. BYL719
(25) and LJM716 (26), provided by Novartis, were resuspended to a stock concentration of 1
mM in DMSO or 10 mg/ml in sterile PBS, respectively. siRNA (Qiagen) were transfected at
a final concentration of 50 nM total siRNA using Lipofectamine RNAiMAX (Life
Technologies) following the manufacturer’s protocol (see Supplementary Methods). The
duration and concentration of each drug or siRNA treatment is described with each figure.
Media and inhibitors were replenished every three days. Colony growth was assessed by
plating cells and staining with crystal violet as detailed in Supplementary Methods.
Mice
To generate the iPIK3.iCre.ErbB3FL/FL model on a congenic FVB background, the
following FVB mouse strains were interbred: MMTV-rtTA (27), Tet-Op-HA-
PIK3CAH1047R-IRES-Luc (28), Tet-Op-Cre (29) and ErbB3FL/FL (30) as described in
Supplementary Methods. Details of tumor transplantation are also provided in
Supplementary Methods. Briefly, harvested tumors were homogenized in serum-free media
with gentleMACS C Tubes (Miltenyi Biotec) and resuspended in 7 ml matrigel diluted with
50% PBS. Tumor homogenates (100 μl) were injected into both inguinal (#4) mammary fat
pads of ~4 week old female athymic mice (Harlan laboratory) using a 25-gauge needle.
When tumors reached ≥125 mm3, mice were randomized to four treatment groups as
indicated in figure legends. Lapatinib di-p-toluenesulfonate salt and imatinib
methanesulfonate salt were purchased from LC Laboratories.
Lapatinib, imatinib and BYL719 were resuspended in 0.5% methyl cellulose, 0.1%
Tween-80 for treatment by orogastric gavage. Lapatinib and imatinib were administered
twice daily at 100 mg/kg/dose and BYL719 once daily at 30 mg/kg/dose. In the first study,
all mice were sacrificed when tumors in vehicle treated mice exceeded 1.5 cm3. In the
second study, animals with tumors greater than 1.0 cm3 were sacrificed and all remaining
animals were sacrificed on day 21. Mice were always sacrificed one hour after drug
treatment.
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Protein and Histological Analyses
Cell line and tumor protein lysates were prepared as described in Supplementary Methods.
Immunoprecipitation was performed with a p85 (Millipore) or an HA antibody (Cell
Signaling) using a ratio of 1 μg antibody: 250 μg lysate: 5 μl Dynal protein G beads (Life
Technologies) with end-over-end rotation at 4°C for 4 h. For immunoblot analysis, equal
amounts of protein/lane were subjected to SDS-PAGE, transferred to nitrocellulose
membranes and analyzed with antibodies as described in Supplementary Methods. Phospho-
RTK arrays were purchased from R&D systems and incubated with 225 μg cell lysates
following manufacturer’s directions. Details of guinea pig anti-cytokeratin 8 (RDI-
Fitzgerald) and rabbit anti-cytokeratin 5 (Covance) immunofluorescent staining of tissue
sections and hematoxylin staining of whole mount mammary glands are provided in
Supplementary Methods.
Gene Expression Analyses
Tumor RNA was harvested from ErbB3FL/+ and ErbB3FL/FL iPIK3.iCre tumors and
analyzed by cDNA microarray as described previously (31, 32). Briefly, RNA isolated by
Qiagen RNeasy mini kit was hybridized to Agilent custom 4X180K microarrays as
previously described (31); the signal from iPIK3.Cre RNA was normalized to the
Herschkowitz et al 2011 murine dataset (32). The mutant PIK3CA gene signature (33) was
calculated for every genotype in the Herschkowitz et al 2011 mouse tumor dataset (32) and
the iPIK3.iCre tumors. The average gene signature scores for each tumor class were plotted
as boxplots to compare mutant PIK3CA-induced gene expression across previously defined
classes (32).
Statistical Analyses
Significant differences (P <0.01) were determined by ANOVA and Bonferroni post-hoc
tests (multiple testing-corrected) or Student’s T-test using Graphpad Prism software.
RESULTS
ErbB3 inhibition sensitizes mutant PIK3CA breast cancer cells to a p110α inhibitor
ErbB3 silencing impairs the proliferative advantage conferred by mutant PIK3CA in HER2-
amplified breast cancer cells (34). However, the impact of ErbB3 in PIK3CA-mutant breast
cells lacking HER2 amplification is less clear. We treated, MDA-MB-453, T47D, BT20 and
CAL-148 breast cancer cells, all harboring PIK3CAH1047R, with the ErbB3 neutralizing
antibody, LJM716 (26), and BYL719, a p110α-specific inhibitor with an IC50 against wild
type and mutant p110α of ≤5 nM (25). BYL719 decreased the proliferation (Fig. 1A–D) and
Akt phosphorylation (Fig. 1E–H) of all four cell lines in a dose-dependent fashion,
suggesting p110αH1047R is a driver of proliferation and PI3K activity in these cells. LJM716
reduced basal and BYL719-induced total and Y1289-P-ErbB3 (Fig. 1E–H) and enhanced
BYL719-mediated growth inhibition in each cell line (Fig. 1A–D), albeit weakly in T47D
and CAL-148 cells. We also utilized EZN-3920, a locked nucleic acid (LNA) ErbB3-
targeted antisense or a scrambled control LNA antisense, EZN-4455 (11, 24), in
combination with BYL719. EZN-3920 did not reduce ErbB3 expression in MDA-MB-453
or T47D cells (Fig. 1I). EZN-3920 reduced ErbB3 levels and BYL719-induced Y1289-P-
ErbB3 in both BT20 and CAL-148 cells (Fig. 1L–M). The combination of
BYL719+EZN-3920 exhibited a better anti-proliferative effect than either agent alone (Fig.
1J–K). Additionally, increased T308-P-Akt induced by EZN-3920 was abrogated by
BYL719 (Fig. 1L–M). These data suggest that co-inhibition of ErbB3 and p110α impairs
the proliferative advantage conferred by mutant PIK3CA in breast cancer cells without
HER2 gene amplification.
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Loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA, but does
not delay tumor formation
To evaluate whether ErbB3 is required for PIK3CAH1047R-induced mammary epithelial cell
(MEC) transformation in vivo, we generated transgenic mice in which doxycycline (DOX)-
induced PIK3CAH1047R drives mammary tumor formation in the presence or absence of
ErbB3. These mice expressed three transgenes [MMTV-rtTA (27), Tet-Op-HA-
PIK3CAH1047R-IRES-Luc (28) and Tet-Op-Cre (29)] and harbored homozygous or
heterozygous floxed ERBB3 alleles (11, 30, 35) (Fig. S1). In this model, referred to as
iPIK3.iCre, DOX treatment simultaneously induced the expression of hemagglutinin (HA)-
tagged PIK3CAH1047R and Cre recombinase in the mammary epithelium, resulting in Cre-
mediated recombination of floxed ERBB3 alleles in MECs expressing PIK3CAH1047R. The
internal ribosomal entry site (IRES)-Luciferase allows bioluminescent detection of cells/
tissues expressing PIK3CAH1047R.
The mammary ductal epithelium in six-week old ErbB3FL/+(control) animals extended
distally past the central lymph node whereas the epithelium of ErbB3FL/FL mice was
maintained proximal to the lymph node (Fig. S2A) (36). At nine weeks, the ErbB3FL/FL
ductal epithelium extended past the lymph node, but remained shorter than that of
ErbB3FL/+ animals (Fig. S2B). Mammary ductal hyperplasia (induced by mutant PIK3CA)
was not apparent in either group at six or nine weeks of age (Fig. S2A,B). By twelve weeks,
ErbB3FL/+ glands exhibited thickened, irregular ductal epithelium indicative of hyperplasia.
However, ErbB3FL/FL iPIK3.iCre glands contained smooth, normal-appearing ducts (Figs.
2A and S2C). Quantitation of epithelial content in whole mounts showed that ErbB3FL/+
glands contained 80% more epithelium than ErbB3FL/FL glands (Fig. 2A). Histological
examination of mammary gland sections from 12-week old animals showed that the
ErbB3FL/+ iPIK3.iCre glands contained multiple cell layers of ductal epithelium, while the
ErbB3FL/FL iPIK3.iCre epithelium was arranged in a single, smooth cell layer (Fig. 2B).
Mice were monitored for expression of PIK3CA-IRES-Luciferase by IVIS bioluminescence
imaging (Fig. S3). Tumor formation was monitored by mammary gland palpation through
600 days of age. Mice lacking the iPIK3 transgene or not induced with DOX failed to
develop tumors or exhibit luciferase activity at any point. The mean mammary tumor
latency was 398 days in ErbB3FL/+ mice as compared to 419 days in ErbB3FL/FL mice
(p=0.72; Fig. 2C). Loss of ErbB3 did not affect the average number of tumors per animal:
1.75 tumors per ErbB3FL/+ mouse and 1.55 tumors per ErbB3FL/FL mouse (p=0.71). These
data suggest that loss of ErbB3 delays early mammary hyperplasia but not cancer formation
in PIK3CAH1047R-expressing mice.
Loss of ErbB3 does not alter PI3K signaling, histology or gene expression in tumors
induced by mutant PIK3CA
Immunoblot analysis revealed loss of ErbB3 expression in ErbB3FL/FL tumors. All tumors
expressed p110α and p85 subunits of PI3K as well as the HA-tagged p110αH1047R
transgene. Levels of phosphorylated Akt, S6 and PDK1 were similar in ErbB3FL/+ and
ErbB3FL/FL tumors, suggesting loss of ErbB3 did not attenuate PI3K signaling in
PIK3CAH1047R-driven mammary tumors (Fig. 2D).
Global gene expression patterns in ErbB3-deficient and ErbB3-competent tumors were
assessed using cDNA microarrays. Unsupervised, hierarchical cluster analysis of iPIK3
tumors and 13 other genetically engineered mouse models (GEMM) of breast cancer (31,
32) demonstrated ErbB3FL/+ tumors did not segregate from ErbB3FL/FL tumors (Fig. 2E).
Two-class significance analysis of microarray (SAM) analysis did not identify any
differentially expressed genes in ErbB3FL/+ and ErbB3FL/FL tumors. A previously reported
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mutant PIK3CA gene expression signature (33) demonstrated that the PIK3CA signature
was higher in the iPIK3.iCre models compared to the other models (Fig. 2F), consistent with
activation of the PI3K pathway. The mutant PIK3CA signature score was similar in
ErbB3FL/+ and ErbB3FL/FL tumors, suggesting loss of ErbB3 did not reduce PI3K signaling
output.
Histological examination of iPIK3 tumors revealed heterogeneous histopathologies (Fig.
S4A). The most frequent histologies were adenocarcinoma and adenocarcinoma with
squamous metaplasia. Squamous metaplasia occurred more frequently in ErbB3FL/FL
samples while metaplastic carcinomas and adenomyoepithelioma-like lesions were unique to
ErbB3FL/+ tumors. ErbB3FL/+ and ErbB3FL/FL tumors often displayed cribriform
architecture, but tumors with papillary architecture occurred more frequently in ErbB3FL/FL
mice and tumors with solid architecture were only seen in ErbB3FL/+ mice (Fig. S4B).
PIK3CA mutant mammary tumors have been reported to co-express both luminal-type (i.e.,
CK8) and basal-type cytokeratins (i.e., CK5) (37, 38). This was seen in ErbB3FL/+ and
ErbB3FL/FL cancers (Fig. S4C). Thus, loss of ErbB3 did not enrich for either the luminal or
basal population. These data are consistent with two recent reports (28, 38).
Mutant p110α binds to ErbB3 and other tyrosine-phosphorylated proteins
Since ErbB3 loss did not attenuate iPIK3.iCre tumorigenesis or PI3K signaling, we sought
to determine if PIK3CAH1047R engaged other tyrosine-phosphorylated adaptors or receptors.
We detected HA-tagged p110αH1047R in p85 immunoprecipitates from ErbB3FL/+ and
ErbB3FL/FL tumor lysates (Fig. 3A, 2nd and 3rd rows). ErbB3 also co-precipitated with p85
in ErbB3FL/+, but not ErbB3FL/FL tumors. Several tyrosine-phosphorylated proteins co-
precipitated with p85 in ErbB3-deficient tumors (Fig. 3A). Immunoprecipitation of mutant
p110α using an anti-HA antibody pulled down p85 and several tyrosine-phosphorylated
proteins in ErbB3FL/+ and ErbB3FL/FL tumor lysates, including ErbB3 in the ErbB3FL/+
tumors (Fig. 3B). p85 or HA frequently co-precipitated IRS-1, a known PI3K scaffold (Fig.
3A–B). ErbB3FL/FL tumors lacked detectable ErbB3, but expressed EGFR, ErbB2, IRS-1
and Gab1/2 at levels similar to ErbB3FL/+ tumors (Fig. 3C). Association of p85 with ErbB3,
Gab1 and IRS-1 in iPIK3 tumor lysates (Fig. 3D) suggests that multiple adaptors can
simultaneously engage mutant p110α, perhaps rendering ErbB3 dispensable for activity and
plasma membrane localization of PIK3CAH1047R.
Because the PIK3CAH1047R -mutant human breast cancer cell line T47D requires mutant
p110α for growth and Akt phosphorylation (Fig. 1B,F), we assessed the requirement for
PI3K-activating adaptors. ErbB3 siRNA reduced co-precipitation of ErbB3 with p85, but
Gab2 and IRS-1 continued to associate with p85 following ErbB3 depletion (Fig. 4A).
Furthermore, P-Akt levels were sustained following ErbB3 depletion, consistent with
maintenance of PI3K signaling. We combined siRNA-mediated knockdown of ErbB3, Gab2
and/or IRS-1. Despite significant reduction of all three PI3K adaptors, Akt remained
phosphorylated, suggesting that PI3K activity was not reduced (Fig. 4B). Similarly,
proliferation was not dramatically altered by combined depletion of ErbB3, Gab2 and IRS-1
(Fig. 4C). These data suggest that because multiple proteins can engage mutant PI3K,
depletion of ErbB3, Gab2 and/or IRS-1 is insufficient to reduce PI3K activity of tumors or
cells driven by PIK3CAH1047R.
ErbB RTK activity is dispensable in PIK3CAH1047R tumors
To determine whether RTKs other than ErbB3 are activated in iPIK3.iCre tumors, we
performed phospho-RTK arrays. The most prominent tyrosine-phosphorylated RTKs in both
ErbB3FL/+ and ErbB3FL/FL tumors were ErbB2, EGFR, PDGFR and macrophage
stimulating protein receptor (MSPR/Ron) (Fig. 5A). One of the eight tumors exhibited high
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P-HGFR, consistent with HGFR (MET) amplification previously reported in this model
(28). We speculate the presence of these phosphorylated RTKs, all capable of engaging
PI3K, may negate a requirement for ErbB3 in iPIK3 tumors.
To determine if inhibition of EGFR, ErbB2 and PDGFR would inhibit growth of
PIK3CAH1047R-expressing mammary tumors, we treated iPIK3.iCre tumor-bearing mice
with 1) vehicle; 2) EGFR/ErbB2 tyrosine kinase inhibitor (TKI) lapatinib; 3) PDGFR TKI
imatinib, and 4) lapatinib + imatinib. Tumor growth was delayed by each single inhibitor
and the combination (Fig. 5B). P-ErbB2 and P-EGFR levels were reduced by lapatinib while
imatinib inhibited P-PDGFRα and P-PDGFRβ (Fig. 5C). Imatinib-treated tumors exhibited
higher levels of P-ErbB2 and P-EGFR, which were abolished in tumors co-treated with
lapatinib. Although the combination of imatinib and lapatinib slowed tumor growth and
inhibited ErbB/PDGFR phosphorylation, Akt and PDK1 remained phosphorylated in tumors
treated with both RTK inhibitors (Fig. 5D). Pull down of p85 from tumor lysates co-
precipitated IRS-1 and Gab1 as well as other tyrosine-phosphorylated proteins (Fig. S5A,B).
These data suggest that mutant PI3K engages multiple upstream adaptors, potentially
explaining how it maintains its activity and effect on tumor growth despite inhibition of
EGFR, ErbB2 and PDGFR kinases with a combination of small molecule inhibitors.
Inhibition of PIK3CAH1047R–driven tumor growth by a p110α inhibitor is enhanced by co-
inhibition of ErbB2/EGFR
Data shown in Figs. 2C–F, 4 and 5B–D suggest that targeted inhibition of signaling events
upstream of PI3K, including ErbB3, EGFR, ErbB2, PDGFR, Gab2 or IRS-1, is insufficient
to silence PI3K activity and tumor growth in PIK3CAH1047R-driven cancers. Further,
compensatory upregulation of signaling networks upstream of PI3K can limit the therapeutic
response to PI3K inhibitors (13, 39). To determine if this occurs in tumors that express
PIK3CAH1047R as the pathogenic oncogene, we treated iPIK3.iCre tumors with 1) vehicle;
2) p110α-specific inhibitor BYL719; 3) lapatinib or 4) lapatinib + BYL719. Although
lapatinib slowed tumor growth less effectively than BYL719, the combination of lapatinib +
BYL719 inhibited tumor growth more potently than either agent alone (Fig. 6A). Lapatinib
reduced EGFR, ErbB2 and ErbB3 phosphorylation (Fig. 6B), but did not decrease P-PDK1
or P-Akt (Fig. 6C). BYL719 alone decreased P-Akt, but not P-PDK1. In contrast, BYL719 +
lapatinib markedly reduced P-Akt and P-PDK1 levels (Fig. 6C), suggesting a more potent
suppression of PI3K when p110α and EGFR/ErbB2/ErbB3 are inhibited simultaneously.
BYL719 + lapatinib treatment slowed the weight gain of adolescent, tumor-bearing mice
compared to mice treated with single agent BYL719 (P < 0.01), but histopathological
analysis revealed no liver damage in any treatment group (Fig. S6).
To extend these observations, four human breast cancer cell lines with PIK3CAH1047R, but
without HER2 gene amplification (MDA-MB-453, T47D, BT20 and CAL-148), were
treated with BYL719 and lapatinib. BYL719 reduced proliferation and P-Akt in all four cell
lines (Fig. 7). Lapatinib inhibited basal and BYL719-induced phosphorylation of EGFR,
ErbB2 and ErbB3 in each cell line (Fig. 7E–H). Lapatinib inhibited the proliferation of two
cell lines as a single agent and aided the anti-proliferative action of BYL719 in all four cell
lines (Fig. 7A–D). Compared to single agent treatments, the combination of BYL719 +
lapatinib resulted in more potent inhibition of S473-P-Akt, T308-P-Akt and P-S6 in MDA-
MB-453 cells; S473-P-Akt, P-ERK and P-S6 in T47D cells; P-PDK1 and P-ERK in BT20
cells; and T308-P-Akt, P-PDK1 and P-ERK in CAL-148 cells (Fig. 7E–H). Thus, while
signaling downstream of PI3K was differentially affected by BYL719 and lapatinib in the
four human cell lines and iPIK3.iCre transgenic mouse tumors, combined inhibition of
p110α and ErbB receptors resulted in a more potent antitumor effect in all five
PIK3CAH1047R-driven models.
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PI3K is the most frequently mutated signaling pathway in breast cancer. Most common
somatic alterations in this pathway are ‘hot spot’ mutations in the helical and catalytic
domains of PIK3CA (8). Transgenic mice with conditional expression of PIK3CAH1047R in
the mammary gland develop mammary cancers (28). Despite exhibiting a ‘gain-of-function,’
mutant PIK3CA still requires binding via the regulatory subunit p85 to phosphorylated
adaptors or receptors. For example, PIK3CAH1047R-mediated transformation of chick
embryo fibroblast depends on its interaction with p85 (21) and the catalytic activity of
PI3KH1047R is enhanced by coupling to phosphorylated PDGFR or IRS-1 (20). Further,
knockdown of ErbB3 or its ligand heregulin inhibits growth and P-Akt levels in cells
expressing PIK3CAH1047R (34). Tissue-specific deletion of ErbB3 in the mammary gland
results in a delay in ductal extension during puberty, increased apoptosis in terminal end
buds (TEBs) and a reduction in P-Akt (36), suggesting ErbB3-activated PI3K has an
important role in mammary gland morphogenesis. Finally, Cre-mediated deletion of ErbB3
prolonged mammary tumor latency, reduced lung metastases and reduced P-Akt levels in
mammary tumors driven by polyomavirus middle T oncogene (PyV mT) (11). In this mouse
model, PyV mT-driven tumor formation is highly dependent upon the association of middle
T with p85 (40) and this association is lost upon deletion of ErbB3 or inhibition of ErbB3
phosphorylation with the EGFR/ErbB2 inhibitor lapatinib (11). These data suggest that
ErbB3 is a major activator of wild type and mutant PI3K in normal and transformed MECs.
Thus, we examined if ErbB3 was required for MEC transformation by mutant PI3K.
We demonstrated herein that loss of ErbB3 delayed mammary gland hyperplasia induced by
mutant PIK3CA, but was dispensable for mammary tumorigenesis. This is in contrast to
mammary tumors induced by the ErbB2/Neu transgene where loss of ErbB3 blocks
mammary tumorigenesis (35). Our data are reminiscent of a recent study by Lahlou et al., in
which ErbB2/Neu-mediated hyperplasia, but not MEC transformation, was reduced by an
ErbB3 mutant incapable of binding to p85 (PI3K) (41). In tumors expressing the PI3K-
uncoupled ErbB3 mutant, ErbB2 and EGFR engaged p85 to maintain PI3K activity. The
iPIK3.iCre mice we present herein are phenotypically similar. It is unclear why genetic
ablation of ErbB3 inhibits Neu-induced tumor formation (35), while uncoupling PI3K from
ErbB3 does not (41), but the results suggest PI3K-independent functions of ErbB3.
Inhibition of EGFR/ErbB2 or PDGFR slowed mutant PIK3CA tumor growth without
affecting Akt and PDK1 phosphorylation. This result suggests two not mutually exclusive
possibilities. First, many RTKs or adaptors might contribute to PI3K activation in tumors
harboring PIK3CA mutations. Second, the heightened activity of the PIK3CAH1047R kinase
domain mutant (42, 43) allows for this kinase to signal strongly with fewer/no upstream
binding partner(s). However, some upstream binding partners are likely needed because
structural data suggest that p85 inhibits the catalytic activity of p110 until the p85/p110
complex binds to consensus phosphotyrosine YXXM motifs in RTKs/adaptors, thus
relieving p85-mediated inhibition of p110 (44). E545K mutation in PIK3CA causes a
structural change in the PI3K holoenzyme such that p85 no longer inhibits p110α, resulting
in increased PI3K activity (45) which cannot be further activated by added tyrosine
phosphorylated peptides (20). In contrast, the high kinase activity of H1047R PI3K doubles
upon the addition of phospho-PDGFR or phospho-IRS-1 peptides (20). Finally, the
transforming action of PIK3CAH1047R, but not PIK3CAE545K, is markedly reduced by loss
of p85 binding, suggesting that PIK3CAH1047R requires binding to RTKs/adaptors for full
activity (6, 21).
The driving oncogene in iPIK3.iCre tumors is PIK3CAH1047R, making PI3K the most
compelling therapeutic target. As a single agent, the p110α-specific inhibitor BYL719
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reduced tumor growth and P-Akt in iPIK3.iCre tumors without effecting P-PDK1. Dual
EGFR/ErbB2 and PI3K inhibition reduced P-Akt and P-PDK1 and decreased tumor growth
better than either agent alone. These data suggest that while individual inhibition of mutant
PI3K and RTKs upstream was insufficient to suppress PI3K activity and growth, ErbB
inhibition significantly enhanced the effect of BYL719 against PI3K mutant cancers. This
was recapitulated in PIK3CAH1047R human breast cancer cells. We speculate, however, that
tumor cells not initially eliminated by combined ErbB and PI3K inhibition may allow
mutant PI3K to engage other RTKs and adaptors, eventually allowing tumors to evade the
antitumor effect of PI3K inhibitors.
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Figure 1. ErbB3 inhibition sensitizes mutant PIK3CA breast cancer cells to a p110α inhibitor
A–D) The indicated cell lines were treated ±10 μg/ml LJM716, ErbB3 blocking antibody
(αErbB3), and 0, 250 or 1,000 nM BYL719 for 15 days (MDA-MB-453 and T47D), 9 days
(BT20) or 12 days (CAL-148). Colonies were stained with crystal violet and quantitated
using Image J software. Values shown are percent growth relative to control treated cells
E–H) Cells were treated as described in panel A–D; after 4 days of treatment cell lysates
were prepared and subjected to immunoblot analysis with the indicated antibodies
I) MDA-MB-453 or T47D cells were treated 7 days with 5 μM LNA antisense molecules
without transfection reagent. EZN-4455, control LNA antisense (C); or EZN-3920, ErbB3-
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targeted LNA antisense (3), were used. Lysates were prepared and subjected to immunoblot
analysis with the indicated antibodies
J–K) BT20 cells were treated 15 days or CAL-148 cells were treated 12 days with 5 μM
control LNA antisense (CTRL) or ErbB3-targeted LNA antisense (ErbB3) without
transfection reagent and 0, 250 or 1,000 nM BYL719. Growth was assessed as described in
panels A–D
L–M) BT20 or CAL-148 cells were treated as described in panels J–K; after 7 days of
treatment cell lysates were prepared and subjected to immunoblot analysis with the indicated
antibodies
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Figure 2. Loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA, but
does not delay tumor formation or alter PI3K signaling or gene expression
A) Whole mount inguinal mammary glands from 12 week old ErbB3FL/+ and ErbB3FL/FL
iPIK3.iCre mice were stained and photomicrographed at 40x power (top) followed by
conversion to binary pictures (bottom). The average percentage of area occupied by
epithelium ±SEM was quantitated from four representative binary photomicrographs (n = 3
per genotype; right). * P < 0.01
B) Representative H&E stained sections of mammary glands harvested from 12 week old
ErbB3FL/+ and ErbB3FL/FL iPIK3.iCre mice photomicrographed at 400x power.
C) Kaplan-Meier analysis of tumor-free survival of 11 ErbB3FL/+ and 13 ErbB3FL/FL
iPIK3.iCre mice. Average tumor latency = T50. P value calculated using log-rank test.
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D) Lysates were prepared from tumors harvested from one ErbB3+/+, four ErbB3FL/+ and
four ErbB3FL/FL iPIK3.iCre mice and were subjected to immunoblot analysis with the
indicated antibodies.
E) Left: Unsupervised hierarchical cluster of six ErbB3FL/+ and six ErbB3FL/FL iPIK3.iCre
tumors with thirteen previously characterized breast cancer GEMMs (32) using all probes
with at least an absolute log2 expression value greater than two on at least three arrays (2203
genes). Right: Enlargement of the array dendrogram with common murine groups that
represent human phenotypes highlighted for reference: MMTV-Neu (luminal), Normal
breast, Claudin-low, and C3-Tag (basal-like). Beneath the dendrogram are twenty classic
genes that segregate the intrinsic subtypes. The iPIK3.iCre dendrogram is enlarged to
discern individual ErbB3FL/+ and ErbB3FL/FL tumors.
F) Genes with a positive fold change in the mutant PIK3CA gene signature of Loi et al (33)
were averaged for each tumor in the combined murine dataset. These values were plotted by
median expression for the defined murine classes (32) and the ErbB3FL/+ and ErbB3FL/FL
iPIK3.iCre tumors.
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Figure 3. Mutant p110α binds to ErbB3 and other tyrosine-phosphorylated proteins
A) p85 was immunoprecipitated (I.P.) from five ErbB3FL/+ and five ErbB3FL/FL primary
tumor lysates. Immune complexes were prepared as indicated in Methods and subjected to
immunoblot analysis with the indicated antibodies.
B) HA-tagged p110αH1047R was immunoprecipitated from the lysates of three ErbB3FL/+
and three ErbB3FL/FL tumors. Immune complexes were analyzed as described in panel A.
C) Lysates of six ErbB3FL/+ and six ErbB3FL/FL iPIK3.iCre primary tumors were evaluated
by immunoblot analysis with the indicated antibodies.
D) An iPIK3.iCre tumor lysate was subjected to immunoprecipitation with control IgG or
p85 antibodies. Whole lysates and antibody pull downs were evaluated by immunoblot
analysis with the indicated antibodies
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Figure 4. Loss of ErbB3, Gab2 and/or IRS-1 does not inhibit Akt or growth of T47D breast
cancer cells
A) Lysates (lys) or p85 immunoprecipitates (I.P.) from T47D cells transfected with control
siRNA (siCTRL) or HER3 siRNA (siHER3) collected 48 hours after transfection were
evaluated by immunoblot analysis with the indicated antibodies.
B) T47D cells were transfected with siRNA targeting ErbB3, Gab2 or IRS-1 as indicated
with control siRNA being used such that 50 nM total siRNA was always used. Lysates were
prepared 48 hours after transfection and evaluated by immunoblot analysis with the
indicated antibodies
C) T47D cells transfected with siRNA as described in panel B were stained with crystal
violet 7 days after transfection
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Figure 5. ErbB RTK activity is dispensable in PIK3CAH1047R tumors
A) The lysates of four ErbB3FL/+ and four ErbB3FL/FL primary tumors were applied to
phospho-RTK arrays. One representative array of each genotype is presented (top) and
enlarged, exposure-matched levels of ErbB2, PDGFRα, EGFR, MSPR and HGFR is
presented (lower).
B) Mice bearing ≥125 mm3 orthotopically-transplanted iPIK3.iCre tumors were treated
twice daily (100 mg/kg/dose) by orogastric gavage with vehicle, lapatinib, imatinib or
lapatinib + imatinib (10 tumors per group). Average tumor volume for each group ±SEM is
plotted against time. * P < 0.01 (vehicle vs. treatment)
C) Three tumor lysates per group were subjected to immunoprecipitation (I.P.) with
antibodies against ErbB2, EGFR, PDGFRα or PDGFRβ. Antibody pull downs were
subjected to immunoblot analysis with a P-Tyr antibody. Membranes were stripped and re-
probed to detect the pulled down RTK.
D) The same tumor lysates as in panel C were evaluated by immunoblot analysis with the
indicated antibodies.
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Figure 6. Growth of PIK3CAH1047R–driven tumors is inhibited by combined blockade of p110α
and ErbB2/EGFR
A) Mice bearing ≥125 mm3 orthotopically-transplanted iPIK3.iCre tumors were treated with
vehicle (twice daily), lapatinib (twice daily at 100 mg/kg/dose), BYL719 (once daily at 30
mg/kg/dose) or lapatinib + BYL719 (14-16 tumors per group). Average tumor volume for
each group ±SEM is plotted against time. * P < 0.01 reported at earliest significant
difference between groups.
B) Tumor lysates were subjected to immunoprecipitation (I.P.) with antibodies against
EGFR, ErbB2 or ErbB3 and the resulting immune complexes evaluated by immunoblot
analysis with a P-Tyr antibody. Membranes were stripped and re-probed to detect the pulled
down RTK.
C) The same tumor lysates as in panel B were evaluated by immunoblot analysis with the
indicated antibodies.
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Figure 7. HER2 non-amplified human breast cancer cells with PIK3CAH1047R are inhibited by
combination of p110α inhibitor and lapatinib
A–D) The indicated cell lines were treated with DMSO or 500 nM lapatinib (Lap) and 0,
250 or 1,000 nM BYL719 for 10 days (MDA-MB-453), 14 days (T47D and BT20) or 12
days (CAL-148). Growth was assessed as described in Figure 1.
E–H) Cells were treated as described in panels A–D; after 3 days of treatment cell lysates
were prepared and subjected to immunoblot analysis with the indicated antibodies.
(D=DMSO; L=lapatinib)
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